Overview

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.
Phase:
Early Phase 1
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Dr. Jeffrey Thomas Stroke Shield Foundation
Treatments:
Deferoxamine